sur Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics to Announce New Oral Obesity Candidate
Protagonist Therapeutics, Inc. will host a webcast and conference call to reveal a new oral obesity development candidate. The event is scheduled for Monday, June 30th, at 4:30 pm ET. Participants can join via the provided US and international dial-in numbers or through a webcast link.
The company plans to share in vitro and pre-clinical proof-of-concept study results during the session. Protagonist continues to advance its biopharmaceutical pipeline, with notable developments including icotrokinra and rusfertide, both currently in advanced clinical phases.
A replay of the conference will be available on Protagonist's Investor Relations webpage post-event. This announcement underscores the company's ongoing commitment to addressing clinically and commercially validated targets through innovative oral drug discovery programs.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Protagonist Therapeutics, Inc.